We read with interest the retrospective analysis of the PainFree SmartShock Technology (SST) cohort by Sterns et al.
1Their results confirm that antitachycardia pacing (ATP) can terminate monomorphic ventricular tachycardias (VTs). However, we are concerned about their recommendation to program multiple ATP sequences.
- Sterns L.D.
- Auricchio A.
- Schloss E.J.
- et al.
Antitachycardia pacing success in implantable cardioverter defibrillators by patient, device, and programming characteristics.
Heart Rhythm. 2022 Oct 19; S1547-5271 (–6): 02517
To read this article in full you will need to make a payment
Purchase one-time access:Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
One-time access price info
- For academic or personal research use, select 'Academic and Personal'
- For corporate R&D use, select 'Corporate R&D Professionals'
Subscribe:Subscribe to Heart Rhythm
Already a print subscriber? Claim online access
Already an online subscriber? Sign in
Register: Create an account
Institutional Access: Sign in to ScienceDirect
- Antitachycardia pacing success in implantable cardioverter defibrillators by patient, device, and programming characteristics.Heart Rhythm. 2022 Oct 19; S1547-5271 (–6): 02517
- Efficacy and safety of appropriate shocks and antitachycardia pacing in transvenous and subcutaneous implantable defibrillators: analysis of all appropriate therapy in the PRAETORIAN trial.Circulation. 2022; 145: 321-329
- Subcutaneous and transvenous defibrillators in arrhythmogenic right ventricular cardiomyopathy: a comparison of clinical and quality-of-life outcomes.JACC Clin Electrophysiol. 2022 Oct 21; S2405-500X (–5): 00846
Published online: December 08, 2022
Funding Sources: The authors have no funding sources to disclose.
Disclosures: Dr Knops reports consultancy fees and research grants from Abbott, Boston Scientific, Medtronic, and Cairdac; and has stock options from AtaCor Medical Inc. All other authors have no conflicts of interest to disclose.
© 2022 Heart Rhythm Society. All rights reserved.
ScienceDirectAccess this article on ScienceDirect
- Reply to the Editor—Programming more ATP sequences is not a case of no harm, no foulHeart RhythmVol. 20Issue 3
- PreviewWe would like to thank van der Stuijt et al for their comments on our article. In their letter, they suggest minimizing antitachycardia pacing (ATP) trains with initial programming, and recommend using more ATP trains only if the initial ATP is successful. This is based on their analysis of the results of the PRAETORIAN study, in which patients with transvenous implantable cardioverter-defibrillators (ICDs) with ATP capability were found to have a borderline greater number of electrical storm events.